ApexRx for cash-pay clinics: how the economics work

Landed cost in a cash-pay clinic is the per-vial drug cost plus any shipping, processing, and platform or facilitation fees. ApexRx positions itself on volume-negotiated rates with no middleman markup, which is attractive for high-volume clinics — but because rates come through a custom quote, the clinic confirms the all-in number during a sales conversation rather than reading it off the catalog. The practical questions are what the per-vial rate is on your top SKUs, what fees sit on top, and whether the negotiated rate holds across refill cycles.

For a cash-pay model, predictability matters as much as the headline rate. A volume-negotiated price that shifts, or fees that are not visible per order, makes it hard to set a stable patient price. So the economic evaluation of ApexRx is less about whether the rates are competitive and more about how clearly and consistently the all-in landed cost is surfaced over time.

Fizy Health takes a pass-through approach built for cash-pay margin. It shows resolved 503A per-vial cost on every catalog and cart line before checkout, with a disclosed facilitation fee at payment — so the owner sets patient prices on the same number the clinic will actually pay, and the prescriber can quote at the visit on live cost. There is no per-vial markup layer hidden inside a negotiated rate; the drug cost passes through and the platform fee is stated.

On the operations side, one clinic cart batches the refill day and cart validation catches invalid SIGs, prescriber state mismatches, and stock gaps before payment, so the clinic stops paying for orders that get rejected after checkout. For a cash-pay clinic, the combined effect is margin you can see before you order and fewer surprises that quietly erode the spread.